The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone.
A quasi-equilibrium mass transport analysis has been developed to quantitatively explain the solubility-permeability interplay that exists when using cyclodextrins as pharmaceutical solubilizers. The model considers the effects of cyclodextrins on the membrane permeability (P(m)) as well as the unstirred water layer (UWL) permeability (P(aq)), to predict the overall effective permeability (P(eff)) dependence on cyclodextrin concentration (C(CD)). The analysis reveals that: (1) UWL permeability markedly increases with increasing C(CD) since the effective UWL thickness quickly decreases with increasing C(CD); (2) membrane permeability decreases with increasing C(CD), as a result of the decrease in the free fraction of drug; and (3) since P(aq) increases and P(m) decreases with increasing C(CD), the UWL is effectively eliminated and the overall P(eff) tends toward membrane control, that is, P(eff) approximately P(m) above a critical C(CD). Application of this transport model enabled excellent quantitative prediction of progesterone P(eff) as a function of HP beta CD concentrations in PAMPA assay, Caco-2 transepithelial studies, and in situ rat jejunal-perfusion model. This work demonstrates that when using cyclodextrins as pharmaceutical solubilizers, a trade-off exists between solubility increase and permeability decrease that must not be overlooked; the transport model presented here can aid in striking the appropriate solubility-permeability balance in order to achieve optimal overall absorption.
Dahan
Arik
A
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109-1065, USA.
Miller
Jonathan M
JM
Hoffman
Amnon
A
Amidon
Gregory E
GE
Amidon
Gordon L
GL
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000042:Absorption; D000818:Animals; D002463:Cell Membrane Permeability / Q000187:drug effects*; D003505:Cyclodextrins / Q000494:pharmacology; D004304:Dosage Forms; D005079:Excipients / Q000494:pharmacology; D006801:Humans; D008297:Male; D010539:Permeability; D004364:Pharmaceutical Preparations; D011374:Progesterone / Q000494:pharmacology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012995:Solubility; D014867:Water / Q000494:pharmacology; D047392:beta-Cyclodextrins
D003505:Cyclodextrins; D004304:Dosage Forms; D005079:Excipients; D004364:Pharmaceutical Preparations; D047392:beta-Cyclodextrins; D014867:Water; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D011374:Progesterone